KOCAA
NBIX icon

Knights of Columbus Asset Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,911
Closed -$2.85M – 383
2024
Q4 		$2.85M Sell
20,911
-1,309
-6% -$162K 0.19% 147
2024
Q3 		$2.56M Sell
22,220
-24,833
-53% -$3.4M 0.17% 160
2024
Q2 		$6.48M Buy
47,053
+485
+1% +$66.5K 0.42% 65
2024
Q1 		$6.42M Buy
46,568
+374
+0.8% +$51.1K 0.46% 54
2023
Q4 		$6.09M Sell
46,194
-1,502
-3% -$173K 0.39% 78
2023
Q3 		$5.37M Buy
47,696
+17,414
+58% +$1.83M 0.49% 52
2023
Q2 		$2.86M Buy
30,282
+10,163
+51% +$993K 0.26% 121
2023
Q1 		$2.04M Buy
20,119
+16,945
+534% +$1.76M 0.2% 174
2022
Q4 		$379K Buy
+3,174
New +$372K 0.04% 264
2021
Q2 		– Sell
-17,146
Closed -$1.67M – 330
2021
Q1 		$1.67M Buy
17,146
+554
+3% +$58.1K 0.16% 206
2020
Q4 		$1.59M Sell
16,592
-10,428
-39% -$1.01M 0.17% 216
2020
Q3 		$2.6M Buy
27,020
+4,721
+21% +$546K 0.32% 107
2020
Q2 		$2.72M Buy
+22,299
New +$2.46M 0.33% 99

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Knights of Columbus Asset Advisors's NBIX Position: Q1 2025 in Review

Knights of Columbus Asset Advisors sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 20,911 shares — an estimated $2.85M sold.

Knights of Columbus Asset Advisors first reported a position in NBIX in Q2 2020 and held it in 13 quarters. The position peaked at $6.48M in Q2 2024. 587 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Knights of Columbus Asset Advisors reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Knights of Columbus Asset Advisors sold 20,911 Neurocrine Biosciences shares in Q1 2025, an estimated $2.85M.
  • Knights of Columbus Asset Advisors first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 13 quarters.
  • Knights of Columbus Asset Advisors's Neurocrine Biosciences position peaked at $6.48M in Q2 2024.
  • 587 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Knights of Columbus Asset Advisors's 13F filing for Q1 2025, filed 7 May 2025.